ADC Therapeutics SA · NYSE (us_market)
Healthcare · Biotechnology · Switzerland
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-03-11$4.88 RISE2026-03-30$3.64 PEAK2026-04-16$4.38 36d | -25.4% 19d | Missed | Missed | — | — | +20.3% 17d | Missed |
DROP2025-10-30$4.63 RISE2025-12-08$3.22 PEAK2026-02-23$4.41 116d | -30.5% 39d | Missed | Missed | — | — | +37.0% 77d | Missed |
DROP2025-06-12$3.67 RISE2025-08-07$2.64 PEAK2025-10-30$4.63 140d | -28.1% 56d | Missed | Missed | — | — | +75.4% 84d | Missed |
DROP2025-06-12$3.67 RISE2025-08-06$2.64 PEAK2025-10-30$4.63 140d | -28.1% 55d | Missed | Missed | — | — | +75.4% 85d | Missed |
DROP2025-06-12$3.67 RISE2025-07-01$2.67 PEAK2025-09-24$3.56 104d | -27.2% 19d | Missed | Missed | — | — | +33.3% 85d | Missed |
DROP2024-12-10$3.48 RISE2025-04-08$1.10 PEAK2025-06-06$3.67 178d | -68.4% 119d | Missed | Missed | — | — | +233.6% 59d | Missed |
DROP2024-12-10$3.48 RISE2025-02-11$1.39 PEAK2025-03-12$1.85 92d | -60.1% 63d | Missed | Missed | — | — | +33.1% 29d | Missed |
DROP2024-07-16$4.01 RISE2024-10-10$2.74 PEAK2024-12-10$3.48 147d | -31.7% 86d | Missed | Missed | — | — | +27.0% 61d | Missed |
DROP2024-04-08$5.09 RISE2024-08-12$2.59 PEAK2024-09-20$3.33 165d | -49.1% 126d | Missed | Missed | — | — | +28.6% 39d | Missed |
DROP2024-02-16$5.29 RISE2024-06-25$2.55 PEAK2024-07-15$4.01 150d | -51.8% 130d | Missed | Missed | — | — | +57.3% 20d | Missed |
DROP2024-02-16$5.29 RISE2024-03-14$3.74 PEAK2024-04-08$5.09 52d | -29.3% 27d | Missed | Missed | — | — | +36.1% 25d | Missed |
DROP2023-07-10$2.37 RISE2023-11-09$0.47 PEAK2024-02-07$4.11 212d | -80.3% 122d | Missed | Missed | — | — | +778.2% 90d | Missed |
DROP2023-05-22$2.66 RISE2023-09-22$0.72 PEAK2023-12-14$1.79 206d | -72.9% 123d | Missed | Missed | — | — | +148.6% 83d | Missed |
DROP2023-05-22$2.66 RISE2023-07-27$1.24 PEAK2023-08-11$1.66 81d | -53.4% 66d | Missed | Missed | — | — | +33.9% 15d | Missed |
DROP2023-02-01$5.45 RISE2023-05-02$1.90 PEAK2023-05-22$2.66 110d | -65.1% 90d | Missed | Missed | — | — | +40.0% 20d | Missed |
1–15 / 26 1 / 2 | |||||||
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1, autologous CAR-T, allogeneic cell therapy, and antibody-drug conjugates. Below are the publicly traded category leaders in each. Each is a well-positioned standalone business ... Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Lead
ADC Therapeutics SA Strong Buy: ZYNLONTA combo trials in r/r DLBCL, key LOTIS-5 data Q2 2026, strong ORR/CR, cash to 2028âread now. Click for this ADCT update.
2026-05-05. The following slide deck was published by ADC Therapeutics SA in conjunction with their 2026 Q1 earnings call.
RBC Capital analyst Leonid Timashev reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $6 price target.
HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $8 price target.
Ameet Mallik, who will discuss our operational performance and recent business highlights, followed by our Chief Financial Officer, Pepe Carmona, who will review our fourth quarter and full year 2025 financial results. Before we begin, I would like to remind listeners that some of the statements made during this conference call will contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The company cautions investors not to place undue reliance on these forward-looking statements.
Ameet Mallik, who will discuss our operational performance and recent business highlights, followed by our Chief Financial Officer, Pepe Carmona, who will review our fourth quarter and full year 2025 financial results. Before we begin, I would like to remind listeners that some of the statements made during this conference call will contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The company cautions investors not to place undue reliance on these forward-looking statements.
Moby summary of ADC Therapeutics S.A.'s Q1 2026 earnings call
Moby summary of ADC Therapeutics S.A.'s Q1 2026 earnings call
Today, we issued a press release announcing our first quarter 2026 financial results and business updates. Before we begin, I would like to remind listeners that some of the statements made during this conference call will contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. ADC Therapeutics is providing this information as of today's date and does not undertake any obligation to update any forward-looking statements contained in this conference call as a result of new information, future events or circumstances, except as required by law.
Today, we issued a press release announcing our first quarter 2026 financial results and business updates. Before we begin, I would like to remind listeners that some of the statements made during this conference call will contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. ADC Therapeutics is providing this information as of today's date and does not undertake any obligation to update any forward-looking statements contained in this conference call as a result of new information, future events or circumstances, except as required by law.
ADC Therapeutics (NYSE:ADCT) reported first-quarter 2026 net product revenue growth for its lymphoma therapy ZYNLONTA and reiterated expectations for multiple upcoming clinical milestones, led by a near-term top-line readout from its Phase 3 LOTIS-5 trial. ZYNLONTA revenue rises to $20 million as c
ADC Therapeutics (NYSE:ADCT) reported first-quarter 2026 net product revenue growth for its lymphoma therapy ZYNLONTA and reiterated expectations for multiple upcoming clinical milestones, led by a near-term top-line readout from its Phase 3 LOTIS-5 trial. ZYNLONTA revenue rises to $20 million as c
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of -10.53% and +5.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of -10.53% and +5.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
ADC Therapeutics beat Q1 2026 revenue and EPS estimates, but market reaction stayed muted as investors await pivotal LOTIS-5 Phase 3 clinical data due in Q2 2026.
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2026, and provided recent operational updates.
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call May 4, 2026 8:30 AM EDTCompany ParticipantsNicole Riley - Head of Investor Relations & Corporate...
ADC Therapeutics SA reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported revenue was USD 20.85 million compared to USD 23.03 million a year...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ADCT | -11.23% | -18.66% | -3.68% | +10.03% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -14.20% | -12.95% | -0.24% | -2.66% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Citadel | multi-strat | 3.38M | $12.68M | 0.02% | Trimmed-32.6% | 2026-03-31 |
| StateStreet | passive | 1.57M | $5.87M | 0.00% | Added+11.3% | 2026-03-31 |
| TwoSigma | quant | 668.0K | $2.51M | 0.00% | Added+459.2% | 2026-03-31 |
| RenTech | quant | 299.3K | $1.12M | 0.00% | New | 2026-03-31 |
| DEShaw | quant | 243.2K | $911.91K | 0.00% | Trimmed-7.6% | 2026-03-31 |
| Wellington | fundamental | 231.1K | $866.49K | 0.00% | Added+8.5% | 2026-03-31 |
| FidelityFMR | fundamental | 172.7K | $647.54K | 0.00% | Added+29.1% | 2026-03-31 |
| TRowePrice | fundamental | 70.0K | $263 | 0.00% | Added+49.8% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | -0.21 | — | — |
| 2026-05-04 | -0.20 | -0.21 | -4.13% |
| 2026-03-10 | -0.27 | -0.04 | +85.09% |
| 2025-11-10 | -0.36 | -0.30 | +17.43% |
| 2025-08-12 | -0.48 | -0.50 | -4.89% |
| 2025-05-14 | -0.40 | -0.36 | +10.74% |
| 2025-03-27 | -0.41 | -0.29 | +29.56% |
| 2024-11-07 | -0.39 | -0.42 | -6.46% |
| 2024-08-06 | -0.46 | -0.38 | +16.89% |
| 2024-05-06 | -0.56 | -0.56 | -0.76% |
| 2024-03-13 | -0.50 | -1.03 | -105.18% |
| 2023-11-07 | -0.63 | -0.58 | +8.46% |
| 2023-08-08 | -0.57 | -0.58 | -1.75% |
| 2023-05-09 | -0.64 | -0.74 | -15.64% |
| 2023-02-28 | -0.05 | -0.10 | -100.00% |
| 2022-11-08 | -0.10 | 0.13 | +233.79% |